The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke

Table 1

Direct and indirect costs of patients with atrial fibrillation treated with rivaroxaban and warfarin in 2019.

Cost type	Costs items	Rivaroxaban	Warfarin	value
		Mean (PPP$)	Mean (PPP$)
Direct medical costs	Physician visit	162	176	0.25
	Medication	1422	999	<0.001
	Diagnosis and lab services	33	217	<0.001
	Physiotherapy and other services	2425	2609	0.95
	Hospitalization	845	889	0.59
Direct nonmedical costs	Transportation, accommodation and meals	856	799	0.59
Indirect costs	Lost income	19531	20864	0.005
Total costs		25275	26554	0.004

Medical equipment, complementary medicine.